CEO of GSK since 2017; previously led GSK Consumer Healthcare and held roles at L'Oréal and Diageo; serves on Microsoft board since 2018; Dame Commander of the Order of the British Empire.
no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY
GSK expects 14 medicines and vaccines each with >£2B sales potential this decade, powered by doubled R&D spend, ADC and oligonucleotide platforms, and AI across the discovery value chain to improve hit rates and accelerate timelines.
Emma Walmsley's six-year tenure on Microsoft's board provides GSK direct exposure to cutting-edge AI and cloud technology, which she is applying across GSK's R&D value chain from target selection to clinical trial design to improve productivity.